Bellevue Group Ag Prothena Corp Public LTD CO Transaction History

Bellevue Group Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 07, 2018	SELL	$10.99 - $44.21 $339,041 - $1.36 Million	-30,850 Closed	0 $0
Q1 2018 May 09, 2018	SELL	$27.95 - $45.04 $13,975 - $22,520	-500 Reduced 1.59%	30,850 $1.13 Million
Q4 2017 Feb 14, 2018	SELL	$35.44 - $63.76 $214,412 - $385,748	-6,050 Reduced 16.18%	31,350 $1.18 Million
Q3 2017 Nov 13, 2017	SELL	$53.83 - $67.75 $193,788 - $243,900	-3,600 Reduced 8.78%	37,400 $2.42 Million
Q2 2017 Aug 14, 2017	BUY	N/A	41,000	41,000 $2.22 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $678M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.